




RSV immunisation decision aid

WA state-wide eligibility, for patients **currently pregnant** or **children under 2 years of age**, **excluding Kimberley/Pilbara regions**. For Kimberley/Pilbara regions, [click here](#).



Child medical risk conditions

- Preterm birth <32 weeks gestational age
- Haemodynamically significant congenital heart disease
- Significant immunosuppression, such as from malignancy, solid organ transplant
- Haematopoietic stem cell transplant, or primary immune deficiencies
- Chronic lung disease requiring ongoing oxygen or respiratory support
- Neurological conditions that impair respiratory function
- Cystic fibrosis with severe lung disease or weight for length <10th percentile
- Trisomy 21 or another genetic condition that increases the risk of severe RSV disease

Maternal immunosuppression

- Active leukaemia or lymphoma, or other generalised malignancy
- Received recent chemotherapy or radiotherapy
- HIV (certain people only)
- SOT or HSCT less than 2 years ago, or are still immunocompromised or taking immunosuppressive drugs, or have graft-versus-host disease
- Immunosuppressive therapy, including bDMARDs or tsDMARDs (biological or targeted synthetic disease-modifying anti-rheumatic drugs), or high-dose corticosteroids
- Certain autoimmune diseases, particularly if they are on highly immunosuppressive therapy;
- Have congenital immunodeficiency

Dosage Information

- 1 dose =
- <5kg = 50mg
- ≥ 5kg and <8 months = 100mg
- ≥ 5 kg and ≥ 8months = 200mg (2x100mg pre-filled syringes).

***Note:** Ensure minimum interval of 6 months between Beyfortus doses.